British journal of clinical pharmacology
-
Br J Clin Pharmacol · Dec 2011
Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study.
Information from the spontaneous reporting system raised the hypothesis of an increased risk of meningioma in patients treated with high doses of cyproterone acetate (CPA). The objective of this study was to test the hypothesis of an increased risk of meningioma among users of high dose CPA as compared with non-users in a medical records computerized database. ⋯ The results of this study support the hypothesis that the exposure to high dose CPA increases the risk of meningioma.